
Thursday, January 14, 2021 9:40:42 AM
HCMC is diluting around 201 billion shares into the market through Series C Preferred stock conversions, enriching the same insiders that already diluted over 80 billion shares into the market through cashless warrants.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160900986
I have been exposing SCAM stocks for over 15 years now. Battin 1000
Volume: | 137,917 |
Day Range: | 16.03 - 16.50 |
Bid: | 14.88 |
Ask: | 16.23 |
Last Trade Time: | 4:05:04 PM EST |
Total Trades: | 2,202 |
Recent HCM News
- HUTCHMED to Announce 2024 Final Results • GlobeNewswire Inc. • 02/19/2025 08:30:00 AM
- HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC • GlobeNewswire Inc. • 01/14/2025 04:00:00 AM
- HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy • GlobeNewswire Inc. • 01/02/2025 12:00:00 AM
- HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture • GlobeNewswire Inc. • 01/01/2025 10:46:43 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/13/2024 11:05:12 AM
- HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib) • GlobeNewswire Inc. • 12/13/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/12/2024 11:02:49 AM
- HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy • GlobeNewswire Inc. • 12/12/2024 04:00:00 AM
- Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer • PR Newswire (US) • 12/04/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/03/2024 11:04:33 AM
- HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer • GlobeNewswire Inc. • 12/03/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/29/2024 11:04:11 AM
- HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms • GlobeNewswire Inc. • 11/28/2024 10:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/22/2024 11:04:42 AM
- HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan • GlobeNewswire Inc. • 11/22/2024 04:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/20/2024 11:03:49 AM
- HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee • GlobeNewswire Inc. • 11/20/2024 09:30:00 AM
- HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress • GlobeNewswire Inc. • 11/06/2024 04:00:00 AM
- HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda • GlobeNewswire Inc. • 10/31/2024 08:30:00 AM
- HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial • GlobeNewswire Inc. • 10/16/2024 04:30:00 AM
- Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 09/26/2024 12:51:52 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/24/2024 10:09:13 AM
- HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda • GlobeNewswire Inc. • 09/24/2024 07:00:00 AM
- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 • GlobeNewswire Inc. • 09/17/2024 03:22:47 PM
- HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer • GlobeNewswire Inc. • 09/09/2024 12:00:00 AM
ConnectM Announces Q1 2025 Preliminary Revenue Guidance of $11.3M, Representing a 100% Year-Over-Year Surge • CNTM • Feb 21, 2025 7:17 AM
Consumer Automotive Finance Inc. (CAFI) Completes Final Steps with FINRA, Expects Name and Ticker Change to Fifty 1 Labs, Inc. (FITY) Within 30 Days • CAFI • Feb 20, 2025 9:00 AM
UAV Corp Unveils AIG's Arrival and Cutting-Edge 3D Printing Technology, Paving the Way for Full-Scale T-Wing UAS Production and the Future of Aerospace and Defense Manufacturing • UMAV • Feb 20, 2025 8:30 AM
North Bay Resources Announces Production of 8.5 Ounces Per Ton Gold Concentrate, Bishop Gold Mill, California • NBRI • Feb 19, 2025 8:59 AM
YCRM ReachOut Technology Returns to Trading: CEO Rick Jordan Lays Out Blockchain CyberSecurity Strategy and Industry-First AI MSP Partnership In Shareholder Letter • YCRM • Feb 18, 2025 11:20 AM
VAYK Confirms No Dilution Following Recent Acquisition and 11 Million Insider Purchase • VAYK • Feb 18, 2025 9:30 AM